Ziltivekimab and Tocilizumab, two monoclonal antibodies against IL6 and its receptor, have been associated with a reduction in CRP levels, showing the anti-inflammatory role of these drugs and suggesting a possible use of these molecules for the treatment of atherosclerotic disease [202,203,204], even if an increased risk of the occurrence of the MACE was observed in patients with rheumatoid arthritis treated with anti-IL6 [205]. This evidence concerns the gene CRP and rheumatoid arthritis.